Zobrazeno 1 - 10
of 92
pro vyhledávání: '"Matthew Reaney"'
Autor:
David Cella, Chieh-I Chen, Ruben G. W. Quek, Ainhoa Uribarren, Matthew Reaney, Vera Mastey, Deborah Collyar, Olivier Chassany
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Introduction: Regulatory agencies encourage the incorporation of the patient voices throughout clinical drug development. Patient-Reported Outcomes (PROs) offer one way of doing this and their use has markedly increased in many therapeutic areas, par
Externí odkaz:
https://doaj.org/article/17a05f7495ab4221b6482f1915164555
Autor:
Marlies Wijsenbeek, Maria Molina-Molina, Olivier Chassany, John Fox, Liam Galvin, Klaus Geissler, Katherine M. Hammitt, Michael Kreuter, Teng Moua, Emily C. O'Brien, Ashley F. Slagle, Anna Krasnow, Matthew Reaney, Michael Baldwin, Natalia Male, Klaus B. Rohr, Jeff Swigris, Katerina Antoniou
Publikováno v:
ERJ Open Research, Vol 8, Iss 2 (2022)
Background An understanding of the experience of patients with progressive fibrosing interstitial lung disease (PF-ILD) is needed to select appropriate patient-reported outcome measures (PROMs) to evaluate treatment effect in clinical trials. Methods
Externí odkaz:
https://doaj.org/article/2b4d0656e26e4705841c755f6e5ab14a
Publikováno v:
Journal of Patient-Reported Outcomes, Vol 4, Iss 1, Pp 1-11 (2020)
Abstract Background Hypertrophic cardiomyopathy (HCM) is a primary myocardial disorder defined by left ventricular hypertrophy that cannot be explained by another cardiac or systemic disease. There is a general lack of knowledge about patients’ per
Externí odkaz:
https://doaj.org/article/e7dcf1e2acb24a178df0146b0fab8e19
Autor:
Diane M. Turner-Bowker, Kristina An Haack, Meaghan Krohe, Andrew Yaworsky, Norma Vivas, Masami Kelly, Godhuli Chatterjee, Emily Chaston, Erin Mann, Matthew Reaney
Publikováno v:
Journal of Patient-Reported Outcomes, Vol 4, Iss 1, Pp 1-18 (2020)
Abstract Background Evolving regulatory guidelines recommend routine assessment of the acceptability of pediatric oral medicines throughout clinical development processes. However, such assessment is problematic owing to a lack of standard methods or
Externí odkaz:
https://doaj.org/article/11da081994464c44b9d955157625df17
Autor:
Eric L. Simpson, Marjolein de Bruin-Weller, Laurent Eckert, Diane Whalley, Isabelle Guillemin, Matthew Reaney, Zhen Chen, Lauren Nelson, Shanshan Qin, Ashish Bansal, Abhijit Gadkari
Publikováno v:
Dermatology and Therapy, Vol 9, Iss 4, Pp 799-805 (2019)
Abstract Introduction The Patient-Oriented Eczema Measure (POEM) assesses patient-reported frequency of atopic dermatitis (AD) symptoms, while the Children’s Dermatology Life Quality Index (CDLQI) measures the impact of skin disease on health-relat
Externí odkaz:
https://doaj.org/article/faa6d4545f0f464cbb1e4fdd7627b41a
Autor:
Vibeke Strand, Laure Gossec, Clare W. J. Proudfoot, Chieh-I Chen, Matthew Reaney, Sophie Guillonneau, Toshio Kimura, Janet van Adelsberg, Yong Lin, Erin K. Mangan, Hubert van Hoogstraten, Gerd R. Burmester
Publikováno v:
Arthritis Research & Therapy, Vol 20, Iss 1, Pp 1-12 (2018)
Abstract Background The phase III MONARCH randomized controlled trial (NCT02332590) demonstrated that in patients with rheumatoid arthritis (RA), sarilumab (anti-interleukin-6 receptor monoclonal antibody) monotherapy is superior to adalimumab monoth
Externí odkaz:
https://doaj.org/article/0f4f3986999d4d779a961f01dcdc58ab
Publikováno v:
Health and Quality of Life Outcomes, Vol 16, Iss 1, Pp 1-13 (2018)
Abstract Background Endometriosis is a common gynecological disorder that causes inflammation and pelvic pain. Endometriosis-related pain is best captured with patient-reported outcome (PRO) measures, however, assessment of endometriosis-related pain
Externí odkaz:
https://doaj.org/article/a8580995fb914bc3a94075fc44017b38
Autor:
Claus Bang Pedersen, Colleen A. McHorney, Lotte Seiding Larsen, Katja Wendicke Lophaven, Anders Holmen Moeller, Matthew Reaney
Publikováno v:
Journal of Dermatological Treatment, Vol 28, Iss 3, Pp 213-220 (2017)
Introduction: The single-item Psoriasis Itch VAS was developed to measure itch intensity within the last 24 hours in psoriasis vulgaris to assess treatment benefit. Its psychometric properties were explored in two trials. Methods: Data from two rando
Externí odkaz:
https://doaj.org/article/2717bdc5c9ae484b94e43a7ff47f1b88
Autor:
Ana Oaknin, Bradley J. Monk, Ignace Vergote, Andreia Cristina de Melo, Yong-Man Kim, Alla S. Lisyanskaya, Vanessa Samouëlian, Hee Seung Kim, Evgeniy A. Gotovkin, Fernanda Damian, Chih-Long Chang, Shunji Takahashi, Jingjin Li, Melissa Mathias, Matthew G. Fury, Cristina Ivanescu, Matthew Reaney, Patrick R. LaFontaine, Israel Lowy, James Harnett, Chieh-I Chen, Krishnansu S. Tewari
Publikováno v:
Scientia
Chemotherapy; Quality of life; Symptoms Quimioterapia; Calidad de vida; Síntomas Quimioteràpia; Qualitat de vida; Símptomes Background In a phase III, randomised, active-controlled study (EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9; R2810-ONC-1676; NCT0
Autor:
Matthew Reaney, Veleka Allen, Amy J. Sehnert, Liang Fang, Albert A. Hagège, Srihari S. Naidu, Iacopo Olivotto
Publikováno v:
PharmacoEconomics - Open. 6:563-574
Currently, there is no patient-reported outcome (PRO) instrument specifically designed to evaluate hypertrophic cardiomyopathy (HCM).We present the development and psychometric validation of a novel PRO measure, the HCM Symptom Questionnaire version